Livestream

Livestream: Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes

Launch Date
10/12/2026 at 08:30 pm EDT
Credit Amount
1
Credit Expires
10/12/2026

Faculty

Edward L. Barnes, MD, MPH
Moderator
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Co-Director, Multidisciplinary Inflammatory Bowel Diseases Center
Director for Clinical Research, Multidisciplinary Inflammatory Bowel Diseases Center
Division of Gastroenterology and Hepatology
University of North Carolina at Chapel Hill
Chapel Hill, NC
Andres J. Yarur, MD
Associate Professor of Medicine
IBD Institute
Cedars Sinai Medical Center
Los Angeles, CA
Angelina Collins, MSN, ANP-BC
Nurse Practitioner
Inflammatory Bowel Disease Center
UC San Diego Health
La Jolla, CA
Explore By Section
Statement of Need Learning Objectives Financial Support Target Audience Credit Information Disclosure Declaration Obtaining Credit

Statement of Need

Obesity is transforming the landscape of inflammatory bowel disease (IBD), shaping disease activity, treatment response, and long-term prognosis. As evidence reveals the impact of excess weight on biologic and JAK inhibitor effectiveness, emerging anti-obesity therapies, including GLP-1 receptor agonists, are creating new opportunities to improve patient outcomes. To stay ahead of this rapidly evolving field, gastroenterologists and multidisciplinary care teams need timely, evidence-based education to confidently integrate obesity management into personalized, stigma-free IBD care.

In this CME Outfitters livestream symposium, expert faculty will identify the immunometabolic mechanisms by which visceral and mesenteric adipose tissue contribute to IBD disease activity, therapeutic attenuation, and surgical risk in people with IBD and obesity. Learners will be shown how to apply appropriate, validated methods to systematically identify and characterize adiposity in people with IBD during routine gastroenterology encounters, including recognition of peoples at highest risk based on adiposity distribution. Faculty will model development of an individualized treatment plan for a patient with IBD and obesity that integrates weight management strategies and addresses the safety and appropriate use of GLP-1 RAs in this population.

This event is neither sponsored by nor endorsed by ACG. 

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Identify the immunometabolic mechanisms by which visceral and mesenteric adipose tissue contribute to IBD disease activity, therapeutic attenuation, and surgical risk in people with IBD and obesity
  • Apply appropriate, validated methods to systematically identify and characterize adiposity in people with IBD during routine gastroenterology encounters, including recognition of peoples at highest risk based on adiposity distribution
  • Develop an individualized treatment plan for a patient with IBD and obesity that integrates weight management strategies and addresses the safety and appropriate use of GLP-1 RAs in this population

Financial Support

This activity is supported by an educational grant from Lilly.

Target Audience

Gastroenterologists, nurse practitioners (NPs), and physician associates (PAs)

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: Provider approved by the California Board of Registered Nursing, Provider # CEP 15510, for 1.00 Contact Hours.

Physician Associates (AAPA): 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Barnes reports the following financial relationships:

Advisory Board: AbbVie Inc.; Abivax; Cristcot; Lilly; Merck & Co., Inc.; Pfizer Inc.; and Sanofi

Consultant: Boomerang Medical, Inc.; Intact Therapeutics, Inc.; Pharmassetx Inc.; Takeda Pharmaceutical Company Limited; and Target RWE

Research Support: Bausch Health Companies, Inc./Salix Pharmaceuticals; Lilly; and Johnson & Johnson

Dr. Yarur reports the following financial relationships:

Advisory Board: AbbVie Inc.; Abivax; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol Myers Squibb; Celltrion USA, Inc.; Cristcot; Johnson & Johnson; Lilly; Merck & Co., Inc.; Pfizer Inc.; Roche; Sanofi; and Takeda Pharmaceutical Company Limited

Research Support: Celltrion

Stock Shareholder (ownership interest): Protillion Biosciences and SRT Therapeutics

Ms. Collins reports the following financial relationships:

Advisory Board: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited

Consultant: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited

Speakers Bureau: AbbVie Inc.; Cristcot; Johnson & Johnson; Lilly; and Takeda Pharmaceutical Company Limited

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Michael Franks, APRN, AGACNP-BC, FNP-BC (Peer Reviewer)
Andrea Perseghin, EdD (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
Leah Zadrozny, DVM, PhD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (0% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

MMS-167-101226-11

Livestream: Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes
Event Date: 10/12/2026 at 08:30 pm EDT
Register